TC
VRTX icon

Trust Company’s Vertex Pharmaceuticals VRTX Stock Holding History

Trust Company’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.9K Hold
38
– – ﹤0.01% 383
2026
Q1 		$17K Hold
38
– – ﹤0.01% 394
2025
Q4 		$17.2K Sell
38
-1
-3% -$431 ﹤0.01% 391
2025
Q3 		$15.3K Hold
39
– – ﹤0.01% 297
2025
Q2 		$17.4K Hold
39
– – ﹤0.01% 285
2025
Q1 		$18.9K Hold
39
– – ﹤0.01% 293
2024
Q4 		$15.7K Hold
39
– – ﹤0.01% 297
2024
Q3 		$18.1K Sell
39
-6
-13% -$2.88K ﹤0.01% 263
2024
Q2 		$21.1K Hold
45
– – ﹤0.01% 247
2024
Q1 		$18.8K Sell
45
-836
-95% -$353K ﹤0.01% 254
2023
Q4 		$358K Sell
881
-56
-6% -$20.7K 0.05% 99
2023
Q3 		$326K Sell
937
-419
-31% -$147K 0.05% 101
2023
Q2 		$477K Sell
1,356
-103
-7% -$34.7K 0.07% 86
2023
Q1 		$460K Buy
1,459
+70
+5% +$21K 0.07% 96
2022
Q4 		$401K Sell
1,389
-107
-7% -$32.6K 0.07% 106
2022
Q3 		$433K Sell
1,496
-392
-21% -$113K 0.09% 87
2022
Q2 		$532K Buy
+1,888
New +$505K 0.11% 81
2015
Q3 		– Sell
-150
Closed -$19K – 392
2015
Q2 		$19K Buy
+150
New +$18.9K 0.01% 254

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

Trust Company's VRTX Position: Q2 2026 in Review

Trust Company held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 38 shares worth $18.9K. The position accounts for ﹤0.01% of the portfolio, ranked #383.

Trust Company first reported a position in VRTX in Q2 2015 and has held it in 18 quarters since. The position peaked at $532K in Q2 2022. 334 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Trust Company held 38 shares of Vertex Pharmaceuticals worth $18.9K as of Q2 2026.
  • Trust Company left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
  • Vertex Pharmaceuticals made up ﹤0.01% of Trust Company's portfolio in Q2 2026, its #383 holding.
  • Trust Company first reported a position in Vertex Pharmaceuticals in Q2 2015 and has held it in 18 quarters since.
  • Trust Company's Vertex Pharmaceuticals position peaked at $532K in Q2 2022.
  • 334 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Trust Company's 13F filing for Q2 2026, filed 10 Jul 2026.